COLLEGE OF MEDICINE, UNIVERSITY OF BASRAH, BASRAH, IRAQ.
Wiad Lek. 2024;77(5):1056-1062. doi: 10.36740/WLek202405127.
Aim: To clarify the association between response to Trastuzumab and molecular expression of TIM-3 and FOXP-3 immune checkpoints.
Materials and Methods: FOXP-3 and TIM-3 expression in peripheral blood was analyzed using qPCR, and the serum level of Trastuzumab was estimated using an immune sorbent enzyme assay.
Results: During treatment with Trastuzumab, the FOXP-3 gene expression showed a significant decline throughout one year of treatment, going from 0.85 at cycle 9 to 0.75 at cycle 17. While the TIM-3 gene expression showed a significant up regulation at cycle 9 to 2.8 fold, followed by a reduction in the fold change from 2.8 to 1.7 in the font of reference gene expression.
Conclusions:FOXP-3 and TIM-3 have the potential to be suggestive markers that can anticipate the response to Trastuzumab, but they are not capable of predicting the likelihood of recurrence.
明确抗人表皮生长因子受体 2 单克隆抗体（Trastuzumab）治疗应答与 TIM-3 和 FOXP-3 免疫检查点分子表达之间的相关性。
采用 qPCR 分析外周血中 FOXP-3 和 TIM-3 的表达，采用免疫吸附酶联测定法估计 Trastuzumab 的血清水平。
在接受 Trastuzumab 治疗期间，FOXP-3 基因表达在整个治疗的 1 年内显著下降，从第 9 个周期的 0.85 降至第 17 个周期的 0.75。而 TIM-3 基因表达在第 9 个周期时显著上调至 2.8 倍，随后参照基因表达的倍数变化从 2.8 降至 1.7。
FOXP-3 和 TIM-3 有可能成为提示性标志物，可预测对 Trastuzumab 的治疗应答，但不能预测复发的可能性。
